Фибрилляция предсердий при гипертрофической кардиомиопатии

В настоящем обзоре представлены современные сведения об особенностях фибрилляции предсердий у лиц с гипертрофической кардиомиопатией. Приводятся данные о распространенности, патогенезе и осложнениях фибрилляции предсердий. В статье представлены современные клинические рекомендации авторитетных научных медицинских сообществ по обсуждаемой проблеме. Подробно освещаются факторы риска возникновения фибрилляции предсердий на фоне гипертрофической кардиомиопатии с демонстрацией результатов различных исследований, посвященных изучению взаимосвязи между факторами риска и вероятностью развития аритмии. Описываются методы выявления, клинические проявления и течение фибрилляции предсердий у больных с гипертрофической кардиомиопатией. Представлены современные литературные данные, посвященные тактике ведения пациентов с фибрилляцией предсердий, рассматриваются подходы к лечению с использованием антикоагулянтов, антиаритмических препаратов, показания для проведения радиочастотной транскатетерной аблации и результаты исследований, посвященные долгосрочной эффективности процедуры. Обсуждается ведение больных в случае невозможности восстановления и поддержания синусового ритма.

1. Maron B.J., McKenna W.J., Danielson G.K. et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42(9):1687-713. doi: 10.1016/s0735-1097(03)00941-0.

2. Gersh B.J., Maron B.J., Bonow R.O. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703-38. doi: 10.1016/j.jacc.2011.10.825.

3. Elliott P.M., Anastasakis A., Borger M.A. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the diagnosis and management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.

4. Ommen S.R., Mital S., Burke M.A. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):e159-e240. doi: 10.1016/j.jacc.2020.08.045.

5. Alphonse P., Virk S., Collins J. et al. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review. Clin Res Cardiol. 2020 Sep 3. doi: 10.1007/s00392-020-01730-w.

6. Беленков Ю.Н., Привалова Е.В., Каплунова В.Ю. и др. Гипертрофическая кардиомиопатия — современное состояние проблемы. Вопросы эпидемиологии и номенклатуры, генетики и патофизиологии, вариантов течения и дифференциального диагноза. Кардиология 2013; 5: 4-12. Belenkov Yu.N., Privalova E.V., Kaplunova V.Yu. et al. Hypertrophic cardiomyopthy — modern state of the problem. Issues of epidemiology and nomenclature, genetics and pathophysiology, variants of course and differential diagnosis. Kardiologiia. 2013; 5: 4-12 [In Russian].

7. Ватутин Н.Т., Тарадин Г.Г., Марон М.С. Гипертрофическая кардиомиопатия: генетические изменения, патогенез и патофизиология. Российский кардиологический журнал. 2014; (5): 35-42. Vatutin N.T., Taradin G.G., Maron M.S. Hypertrophic cardiomyopathy: genetic alterations, pathogenesis and pathophysiology. Russian Journal of Cardiology. 2014; (5): 35-42. doi: 10.15829/1560-4071-2014-5-35-42 [In Russian].

8. Каплунова В.Ю., Беленков Ю.Н., Привалова Е.В. и др. Вопросы этиологии, патофизиологии и вариантов течения гипертрофической кардиомиопатии. Журнал Сердечная Недостаточность. 2013; 14(3): 141-148. Kaplunova V.Yu., Belenkov Yu.N., Privalova E.V. et al. Issues of etiology, pathophysiology and variants of the course of hypertrophic cardiomyopathy. Russian Heart Failure Journal 2013; 14(3): 141-148 [In Russian].

9. Teekakirikul P., Zhu W., Huang H.C. et al. Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules. 2019; 9(12): 878. doi: 10.3390/biom9120878.

10. Ahluwalia M., Ho C.Y. Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy. Heart. 2020: heartjnl-2020-316798. doi: 10.1136/heartjnl-2020-316798.

11. Ватутин Н.Т., Тарадин Г.Г., Картамышева Е.В. Нарушения ритма сердца при гипертрофической кардиомиопатии. Вестник аритмологии. 2016; (86): 43-50. Vatutin N.T., Taradin G.G., Kartamysheva E.V. Cardiac arrhythmias in hypertrophic cardiomyopathy. Vestnik aritmologii. 2016; (86): 43-50 [In Russian].

12. Adabag A.S., Casey S.A., Kuskowski M.A. et al. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005; 45(5): 697-704. doi: 10.1016/j.jacc.2004.11.043.

13. Adabag A.S., Maron B.J., Appelbaum E. et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008; 51(14): 1369-74. doi: 10.1016/j.jacc.2007.11.071.

14. Целуйко В.И., Мордяшова С.В. Нарушения ритма сердца у больных гипертрофической кардиомиопатией. Международный медицинский журнал. 2008; 3: 29-33. Tseluyko V.I., Mordyashova S.V. Disorders of the heart rhythm in patients with hypertrophic cardiomyopathy. International Medical Journal 2008; 3: 29-33. [In Russian].

15. Gu S., Liu Z., Liu Z. Prevalence and related factors of arrhythmias in patients with hypertrophic cardiomyopathy. Heart 2012; 98 (suppl. 2): E248-E249. doi: 10.1136/heartjnl-2012-302920q.5

16. Ватутин Н.Т., Тарадин Г.Г., Марон М.С. и др. Внезапная сердечная смерть у больных гипертрофической кардиомиопатией. Кардио логия. 2016; 56(1): 56-65. Vatutin N.T., Taradin G.G., Maron M.S., et al. Sudden cardiac death in patients with hypertrophic cardiomyopathy. Kardiologiia. 2016; 56(1): 56-65. doi: 10.18565/cardio.2016.1.56-65 [In Russian].

17. MacIntyre C., Lakdawala N.K. Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2016; 133(19): 1901-5. doi: 10.1161/CIRCULATIONAHA.115.015085.

18. Zegkos T., Efthimiadis G.K., Parcharidou D.G. et al. Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortality. Hellenic J Cardiol. 2017; 58(5): 331-339. doi: 10.1016/j.hjc.2017.01.027.

19. Hindricks G., Potpara T., Dagres N. et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020: ehaa612. doi: 10.1093/eurheartj/ehaa612.

20. Garg L., Gupta M., Sabzwari S.R. A. et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019; 24(2): 189-197. doi: 10.1007/s10741-018-9752-6.

21. Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104(21): 2517-24. doi: 10.1161/hc4601.097997.

22. Богачев-Прокофьев А.В., Железнев С.И., Фоменко М.С. и др. Эффективность сочетанного лечения фибрилляции предсердий у пациентов с обструктивной гипертрофической кардиомиопатией. Вестник аритмологии. 2016; 84: 12-16. Bogachev-Prokofyev A.V., Zheleznev S.I., Fomenko M.S. et al. Effectiveness of combination treatment of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy. Vestnik aritmologii. 2016; 84: 12-16 [In Russian].

23. Kubo T., Kitaoka H., Okawa M. et al. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study. Circ J. 2009; 73(9): 1599-605. doi: 10.1253/circj.cj-09-0140.

24. Thyagarajan B., Kalra A., Rajabali A. et al. Subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy. US Cardiology Review 2016; 10(2): 75-7. doi: 10.15420/usc.2016:7:2.

25. Siontis K.C., Geske J.B., Ong K. et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014; 3(3): e001002. doi: 10.1161/JAHA.114.001002.

26. Guttmann O.P., Rahman M.S., O’Mahony C. et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014; 100(6): 465-72. doi: 10.1136/heartjnl-2013-304276.

27. Mizia-Stec K., Caforio A.L. P., Charron P. et al. Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/ Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. ESC Heart Fail. 2020; 7(6): 3601–9. doi: 10.1002/ehf2.12854.

28. Philipson D.J., Rader F., Siegel R.J. Risk factors for atrial fibrillation in hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2019: 2047487319828474. doi: 10.1177/2047487319828474.

29. Jung H., Yang P.S., Sung J.H. et al. Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost. 2019; 119(2): 285- 293. doi: 10.1055/s-0038-1676818.

30. Miller C.A. S., Maron M.S., Estes N.A. M III. et al. Safety, side effects and relative efficacy of medications for rhythm control of atrial fibrillation in hypertrophic cardiomyopathy. Am J Cardiol. 2019; 123(11): 1859-1862. doi: 10.1016/j.amjcard.2019.02.051.

31. Kodani E., Akao M. Atrial fibrillation and stroke prevention: state of the art — epidemiology and pathophysiology: new risk factors, concepts and controversies. Eur Heart J Suppl, 2020; 22 Supplement_O;O1–O13. doi: 10.1093/eurheartj/suaa176.

32. Olshansky B., Heller EN., Mitchell L.B. et al. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005; 45(12): 2026-33. doi: 10.1016/j.jacc.2005.03.020.

33. Крылова Н.С., Демкина А.Е., Хашиева Ф.М., и др. Фибрилляция и трепетание предсердий у больных с гипертрофической кардиомиопатией. Российский кардиологический журнал. 2015; (5): 64-70. doi:10.15829/1560-4071-2015-5-64-70. Krylova N.S., Demkina A.E., Khashieva F.M., et al. Atrial fibrillation and flutter in hypertrophic cardiomyopathy. Russian Journal of Cardiology. 2015; (5): 64-70. doi:10.15829/1560-4071-2015-5-64-70 [In Russian].

34. Rowin E.J., Hausvater A., Link M.S. et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017; 136(25): 2420-2436. doi: 10.1161/CIRCULATIONAHA.117.029267.

35. Camm C.F., Camm A.J. Atrial fibrillation and anticoagulation in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev. 2017; 6(2): 63-68. doi: 10.15420/aer.2017.4.2.

36. Kowallick J.T., Silva Vieira M., Kutty S. et al. Left atrial performance in the course of hypertrophic cardiomyopathy: relation to left ventricular hypertrophy and fibrosis. Invest Radiol. 2017; 52(3): 177- 185. doi: 10.1097/RLI.0000000000000326.

37. Maron B.J., Haas T.S., Maron M.S. et al. Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol. 2014; 113(8): 1394-400. doi: 10.1016/j.amjcard.2013.12.045.

38. Tuluce K., Yakar Tuluce S., Kahya Eren N. et al. Predictors of future atrial fibrillation development in patients with hypertrophic cardiomyopathy: a prospective follow-up study. Echocardiography. 2016; 33(3): 379-85. doi: 10.1111/echo.13093.

39. Girasis C., Vassilikos V., Efthimiadis G.K. et al. Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. Eur Heart J Cardiovasc Imaging. 2013; 14(5): 425-34. doi: 10.1093/ehjci/jes172.

40. Debonnaire P., Joyce E., Hiemstra Y. et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017; 10(2): e004052. doi: 10.1161/CIRCEP.116.004052.

41. Yang H., Woo A., Monakier D. et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. J Am Soc Echocardiogr. 2005; 18(10): 1074-82. doi: 10.1016/j.echo.2005.06.011.

42. Богданов Д.В. Сферическое ремоделирование левого предсердия при гипертрофической необструктивной кардиомиопатии. Кардиология 2012; 4: 49-52. Bogdanov D.V. Spherical remodeling of left atrium in hypertrophic non-obstructive cardiomyopathy. Kardiologiia 2012; 4: 49-52 [In Russian].

43. Goette A., Bukowska A., Lillig C.H. et al. Oxidative stress and microcirculatory flow abnormalities in the ventricles during atrial fibrillation. Front Physiol. 2012; 3: 236. doi: 10.3389/fphys.2012.00236.

44. Yamaji K., Fujimoto S., Yutani C. et al. Does the progression of myocardial fibrosis lead to atrial fibrillation in patients with hypertrophic cardiomyopathy? Cardiovasc Pathol. 2001; 10(6): 297-303. doi: 10.1016/s1054-8807(01)00086-2.

45. Goette A., Kalman J.M., Aguinaga L. et al. Document Reviewers. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016; 18(10): 1455-1490. doi: 10.1093/europace/euw161.

46. Kumar K.R., Mandleywala S.N., Link M.S. Atrial and ventricular arrhythmias in hypertrophic cardiomyopathy. Card Electrophysiol Clin. 2015;7(2):173-86. doi: 10.1016/j.ccep.2015.03.002.

47. Sivalokanathan S., Zghaib T., Greenland G.V. et al. Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging. JACC Clin Electrophysiol. 2019; 5(3): 364-375. doi: 10.1016/j.jacep.2018.10.016.

48. Pujadas S., Vidal-Perez R., Hidalgo A. et al. Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Eur J Radiol. 2010; 75(2): e88-91. doi: 10.1016/j.ejrad.2009.12.012.

49. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008; 51(8): 802-9. doi: 10.1016/j.jacc.2007.09.064.

50. Ozdemir O., Soylu M., Demir A.D. et al. P-wave durations as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2004; 94(2-3): 163-6. doi: 10.1016/j.ijcard.2003.01.001.

51. Köse S., Aytemir K., Sade E. et al. Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersion. Clin Cardiol. 2003; 26(9): 431-4. doi: 10.1002/clc.4960260910.

52. Kubo T., Kitaoka H., Okawa M. et al. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin Cardiol. 2010; 33(2): E1-7. doi: 10.1002/clc.20622.

53. Moreno V., Hernández-Romero D., Vilchez J.A. et al. Serum levels of high-sensitivity troponin T: a novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail. 2010; 16(12): 950-6. doi: 10.1016/j.cardfail.2010.07.245.

54. Nakamura S., Takano H., Matsuda J. et al. Prognostic values of highly sensitive cardiac troponin T and B-type natriuretic peptide for clinical features in hypertrophic obstructive cardiomyopathy: a cross-sectional study. BMJ Open. 2014; 4(9): e005968. doi: 10.1136/bmjopen-2014-005968.

55. Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003; 348(4): 295-303. doi: 10.1056/NEJMoa021332.

56. Autore C., Bernabò P., Barillà C.S. et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol. 2005; 45(7): 1076-80. doi: 10.1016/j.jacc.2004.12.067.

57. Park K.M., Im S.I., Kim E.K. et al. Atrial fibrillation in hypertrophic cardiomyopathy: is the extent of septal hypertrophy important? PLoS One. 2016; 11(6): e0156410. doi: 10.1371/journal.pone.0156410.

58. Prinz C., Bitter T., Oldenburg O. et al. Incidence of sleep-disordered breathing in patients with hypertrophic cardiomyopathy. Congest Heart Fail. 2011; 17(1): 19-24. doi: 10.1111/j.1751-7133.2010.00196.x.

59. Holmqvist F., Platonov P.G., Carlson J. et al. Variable interatrial conduction illustrated in a hypertrophic cardiomyopathy population. Ann Noninvasive Electrocardiol. 2007; 12(3): 227-36. doi: 10.1111/j.1542-474X.2007.00166.x.

60. Shigematsu Y., Hamada M., Nagai T. et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol. 2011; 58(1): 18-25. doi: 10.1016/j.jjcc.2011.03.001.

61. Стрельцова А.А., Гудкова А.Я., Костарева А.А. Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии. Consilium Medicum. 2018; 20(5): 34–39. Streltsova A.A., Gudkova A.Ya., Kostareva A.A. Atrial fibrillation in hypertrophic cardiomyopathy: modern aspects of epidemiology, risk factors, pathogenesis and medication-assisted treatment. Consilium Medicum. 2018; 20(5): 34–39. doi: 10.26442/2075-1753_2018.5.34-39 [In Russian].

62. Фибрилляция и трепетание предсердий. Клинические рекомендации МЗ Российской Федерации, 2020; 185 с. [Электронный ресурс]. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf (дата обращения: 07.01.2021). Atrial fibrillation and flutter. Clinical guidelines of the Ministry of Health of the Russian Federation, 2020; 185 р. [Electronic resource]. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_FP_TP.pdf (date of the application: 07.01.2021) [In Russian]

63. Гипертрофическая кардиомиопатия. Клинические рекомендации МЗ Российской Федерации, 2020; 151 c. [Электронный ресурс]. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsiigipertroficheskaja-kardiomiopatija-utv-minzdravom-rossii_1/ (дата обращения: 07.01.2021). Hypertrophic cardiomyopathy. Clinical guidelines of the Ministry of Health of the Russian Federation, 2020; 151 р. [Electronic resource]. URL: https://legalacts.ru/doc/klinicheskie-rekomendatsiigipertroficheskaja-kardiomiopatija-utv-minzdravom-rossii_1/ (date of the application: 07.01.2021) [In Russian]

64. Patten M., Pecha S., Aydin A. Atrial fibrillation in hypertrophic cardiomyopathy: diagnosis and considerations for management. J Atr Fibrillation. 2018; 10(5): 1556. doi: 10.4022/jafib.1556.

65. Azarbal F., Singh M., Finocchiaro G. et al. Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart. 2014; 100(8): 624-30. doi: 10.1136/heartjnl-2013-304908.

66. January C.T., Wann L.S., Alpert J.S. et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): e1-76. doi: 10.1016/j.jacc.2014.03.022.

67. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019 Jul 9; 74(1): 104-132. doi: 10.1016/j.jacc.2019.01.011.

68. Granger C.B., Alexander J.H., McMurray J.J. et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-92. doi: 10.1056/NEJMoa1107039.

69. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1-e88. doi: 10.1093/ejcts/ezw313.

70. Ammirati E., Contri R., Coppini R. et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016; 18(9): 1106-18. doi: 10.1002/ejhf.541.

71. Габрусенко С.А., Сафрыгина Ю.В., Наумов В.Г. и др. Современные подходы к лечению больных гипертрофической кардиомиопатией. Лечащий врач 2004; 2: 32-37. Gabrusenko S.A., Safrygina Yu.V., Naumov V.G., et al. Modern approaches to the treatment of patients with hypertrophic cardiomyopathy. Lechaschy Vrach. 2004; 2: 32-37 [In Russian].

72. Robinson K., Frenneaux M.P., Stockins B. et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol. 1990; 15(6): 1279-85. doi: 10.1016/s0735-1097(10)80014-2.

73. Бокерия Л.А. Гипертрофическая обструктивная кардиомиопатия. Анналы хирургии. 2013; 5:5-14. Bockeria L.A. Hypertrophic obstructive cardiomyopathy. Annals of Surgery. 2013; 5:5-14 [In Russian].

74. Sherrid M.V., Barac I., McKenna W.J. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005; 45(8): 1251-8. doi: 10.1016/j.jacc.2005.01.012.

75. Tendera M., Wycisk A., Schneeweiss A. et al. Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology. 1993; 82(5): 335-42. doi: 10.1159/000175883.

76. Contreras-Valdes F.M., Buxton A.E., Josephson M.E. et al. Atrial fibrillation ablation in patients with hypertrophic cardiomyopathy: long-term outcomes and clinical predictors. J Am Coll Cardiol. 2015; 65(14): 1485-7. doi: 10.1016/j.jacc.2014.12.063.

77. Di Donna P., Olivotto I., Delcrè S.D. et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace. 2010; 12(3): 347-55. doi: 10.1093/europace/euq013.

78. Gaita F., Di Donna P., Olivotto I. et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2007; 99(11): 1575-81. doi: 10.1016/j.amjcard.2006.12.087.